arrow
G

Guillermo Garcia-Manero

the university of texas-md anderson cancer center
H指数:149
被引数:8.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS

口服三联方案(地西他滨/西达苯胺、维奈克拉和吉列替尼)用于新诊断和复发/难治性FLT3突变急性髓系白血病及高风险骨髓增生异常综合征

2026-10-130
OAAI
Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms

Li-Fraumeni综合征合并髓系肿瘤的成人患者预后

Cancer
IF5.1
2026-09-180
OAAI
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

新诊断急性髓系白血病中NPM1突变相关的临床结局

Cancer
IF5.1
2026-08-130
OAAI
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL

Ph1阴性B-ALL一线治疗使用blinatumomab后复发的预测因素及复发后结局

2026-05-170
OAAI
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

低强度治疗下急性髓系白血病中ASXL1突变的预后影响

Cancer
IF5.1
2026-05-060
OA
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

DDX41突变髓系肿瘤挑战现有的预后方案,并需要专门的危险评分系统:一项多中心、回顾性研究

Leukemia
IF13.4
2025-12-030
PRE
Decitabine-cedazuridine in patients with MDS and TP53 mutations

地西他滨-西达佐鲁定在伴TP53突变的患者中的研究

2025-11-140
OAAI
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

2025年白血病研究进展回顾:通过MD Anderson白血病研究视角进行审视

Cancer
IF5.1
2025-10-230
OAAI
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

MECOM融合伙伴和骨髓原始细胞百分比影响MECOM重排急性髓系白血病患者预后

2025-09-220
PRE